Cumberland Pharmaceuticals Deal History & Licensing Activity
Cumberland Pharmaceuticals is a specialty pharma. Over the past three years, Cumberland Pharmaceuticals has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (3 deals). The company currently has 2 active clinical trials, primarily in Other.
Deals (12mo)
2
Active Trials
2
Top Modality
Small Molecules
Focus Area
Other
Cumberland Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Cumberland Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Cumberland's line of branded pharmaceuticals | Apotex | Small Molecules | Approved | acquisition | Jul 1, 2026 |
Cumberland Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Cumberland Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Cumberland Pharmaceuticals Clinical Pipeline
Cumberland Pharmaceuticals has 2 active clinical trials across 1 development phase.
2
Phase 2
See How Your Asset Matches Cumberland Pharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Cumberland Pharmaceuticals Licensing & Deal Activity
Cumberland Pharmaceuticals is a specialty pharma company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Cumberland Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Cumberland Pharmaceuticals include Other (2 deals and trials), Infectious Disease (1 deal and trial), Respiratory (1 deal and trial), and Autoimmune (1 deal and trial). In terms of modality, Cumberland Pharmaceuticals has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Cumberland Pharmaceuticals and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Cumberland Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.